For Healthcare Professionals

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies

clipboard-pencil

About the study

This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Key Inclusion Criteria:

  1. Age ≥ 18 years
  2. Relapsed/metastatic solid tumors treated with prior adequate standard of care therapy for tumor type and stage of disease or where in the opinion of the Investigator, a clinical trial is the best option for the next treatment based on response and/or tolerability to prior therapy.
  3. Measurable disease per RECIST v1.1
  4. Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
  5. Life expectancy ≥ 12 weeks
  6. Adequate organ and marrow function as defined in the protocol

For Sub-Study 1 Part A:

• Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC or endometrial cancer

For Sub-Study 1 Part B:

* Histologically or cytologically confirmed metastatic or locally advanced and recurrent disease for the respective cohort:

  1. Cohort B1 (Biliary Tract Cancer)
  2. Cohort B2 (Ovarian Cancer)
  3. Cohort B3 (Breast Cancer)
  4. Cohort B4 (Endometrial Cancer)
  1. For Sub-Study 2 Part A:
  2. Minimum body weight ≥ 30 kg.
  3. Histologically or cytologically confirmed metastatic or locally advanced/recurrent breast cancer, ovarian cancer, BTC or endometrial cancer.

EXCLUSION CRITERIA

Exclusion Criteria:

* Treatment with any of the following:

  1. Nitrosourea or mitomycin C within 6 weeks prior to the first dose of study treatment
  2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 28 days (whichever is shorter) prior to the first dose of study treatment
  3. Any other anticancer treatment within the following time periods prior to the first dose of study intervention:
  1. Cytotoxic treatment: 21 days
  2. Non-cytotoxic drugs: 21 days or 5 half-lives (whichever is shorter)
  3. Biological products including immuno-oncology agents: 28 days
  4. Spinal cord compression or a history of leptomeningeal carcinomatosis.
  5. Brain metastases unless treated, asymptomatic, stable, and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study.
  6. Active infection including tuberculosis and HBV, HCV or HIV
  7. History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  8. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  9. Participants with any of the following cardiac criteria:
  1. History of arrhythmia which is symptomatic or requires treatment (NCI CTCAE v5.0 Grade 3); symptomatic or uncontrolled atrial fibrillation, or asymptomatic sustained ventricular tachycardia.
  2. Uncontrolled hypertension.
  3. Acute coronary syndrome/acute myocardial infarction, unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention, or coronary artery bypass grafting within 6 months.
  4. History of brain perfusion problems (eg, carotid stenosis) or stroke, or transient ischemic attack in the last 6 months prior to screening.
  5. Symptomatic heart failure (NYHA class ≥ 2).
  6. Prior or current cardiomyopathy.
  7. Severe valvular heart disease.
  8. Mean resting QTcF > 470 msec.
  9. Risk factors for QTc prolongation or risk of arrhythmic events such as heart failure, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age.

Additional Exclusion Criteria for Part A Sub study 2

  1. Thromboembolic event within 3 months before the first dose of study intervention.
  2. Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
  3. Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-877-240-9479Email iconEmail Study Center

Study Details


Contition

Breast Cancer,Biliary Tract Carcinoma,Ovarian Cancer,Endometrial Cancer

Age

18+

Phase

PHASE1/PHASE2

Participants Needed

340

Est. Completion Date

Dec 30, 2025

Treatment Type

INTERVENTIONAL


Sponsor

AstraZeneca

ClinicalTrials.gov NCT Identifier

NCT05123482

Study Number

D6900C00001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.